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Abstract 
Background: Our group has developed a non-invasive blood-based microRNA (miRNA) test 
for improving diagnosis, disease-monitoring and relapse detection in malignant testicular germ 
cell tumors (TGCTs). Performance analysis suggests the test is likely to have comparable 
sensitivity and specificity in detecting TGCT as CT, thus reducing the need for serial CT scans 
for follow-up monitoring, with associated reductions in cumulative radiation burden and 
second cancer risk. To facilitate clinical adoption, we undertook a cost analysis to identify the 
budget impact of replacing CT scans with miRNA testing within healthcare systems. 
Methods: The TGCT aftercare pathway was mapped out using National Comprehensive 
Cancer Network guidelines. A Markov model was built to simulate the impact of the miRNA 
test on TGCT aftercare costs. Incidence, treatment probabilities, relapse rate and death rate data 
were collected from published studies to populate the model. 
Results: Applying our model to the US healthcare system, the miRNA test has the potential to 
save up to $69M/year in aftercare expenses related to TGCT treatment; with exact savings 
depending on the adoption rate and test price. 
Conclusions: This analysis demonstrates the potential positive budget impact of adopting 
miRNA testing in place of CT scans in the clinical management of TGCTs. 
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Introduction 
Germ cell tumors (GCTs) occur throughout life from childhood through to late 
adulthood. They may arise at gonadal (testicular/ovarian) or extragonadal sites. Testicular 
GCTs (TGCTs) are the most common solid malignancy in males aged 20-35 years (1). TGCTs 
are subdivided into seminoma or nonseminoma, the latter group which includes yolk sac tumor, 
embryonal carcinoma and choriocarcinoma (2). Although the cause of testicular cancer is still 
poorly understood, there is increased risk amongst first-degree relatives (1), confirmed by 
recent genome-wide association studies (3).  
Global incidence of TGCTs was 1.5/100,000 in 2008, but is higher in Western Europe 
at 7.8/100,000 (2015 figures) (4). Remission rates are generally high, with 5-year overall 
survival reaching 98%. Following definitive treatment [orchidectomy and 
chemotherapy/radiotherapy according to disease stage (5,6)], there is a risk of recurrence. 
Follow-up schedules generally last for ten years to monitor for this risk and for late-effects of 
treatment (6,7). 
Follow-up typically comprises regular physical examination, serum biomarker 
measurement [alpha-fetoprotein (AFP) and human choriogonadotropin (HCG)] (6), chest X-
rays, and CT scans (7). However, doubt has been cast on the clinical value of physical 
examination (8,9), chest X-ray (10,11), and AFP/HCG markers, which are, for example, 
elevated in just 3% of seminoma patients at relapse (6). Thus for many patients, detection of 
relapse is dependent upon serial CT scans, which are associated with cumulative radiation 
burden and increased second cancer risk (12). Consequently, there is a clear need for a 
universal, reliable alternative to current biomarkers and CT scans for disease-monitoring 
purposes, both during and after treatment (7).  
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MicroRNAs (miRNAs) are short, non-coding RNAs which regulate gene expression 
(2). Global miRNA expression profiles classify cancer more effectively than protein-coding 
messenger RNAs (mRNAs) and reflect the developmental lineage of tumors (13). Our previous 
work showed that all malignant GCTs overexpress miRNAs from the miR-371~373 and miR-
302/367 clusters, independent of patient age (pediatric or adult), tumor histological subtype 
(seminoma, yolk sac tumor or embryonal carcinoma) or anatomic site (gonadal or 
extragonadal), and are not coordinately overexpressed in any other cancer or disease state, 
demonstrating their biomarker potential (2,6). Furthermore, using PCR methodology 
incorporating a pre-amplification step, these miRNAs were elevated in serum at the time of 
malignant GCT diagnosis, and fell to normal levels during successful treatment (14). This and 
further work (6,15-18), subsequently replicated by others (e.g. (19-22)), has for example shown 
that miRNA marker sampling is also highly sensitive for detecting relapse in TGCT follow-up 
(17). MiR-371a-3p use as a serum biomarker has been shown to achieve a 
sensitivity/specificity of 88.7/93.4%, respectively, with an area under the curve (AUC) on 
receiver operator characteristic analysis of 0.94 (20). The combined use of miR-371a-3p 
together with miR-373-3p and miR-367-3p under pre-amplification conditions was found to 
yield sensitivity of 92% and specificity of 91% (22). Serial testing of miRNAs (as is currently 
undertaken with AFP/HCG), would therefore put miRNA testing in contention with CT 
scanning for TGCT recurrence monitoring, which itself has a sensitivity and specificity of 
92.8% and 98.6%, respectively (23). Indeed, an independent review highlighted the 
translational potential of this non-invasive blood-based miRNA test, stating that the data thus 
far ‘provides convincing evidence for the use of miRNAs as biomarkers for (germ cell) 
testicular cancer’ and that the ‘introduction of miRNA measurements is anticipated for the 
clinical management of patients with TGCTs in the near future’ (24). 
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However, prior to the introduction of novel nucleic acid based biomarkers such as 
circulating miRNAs or tumor DNA (ctDNA) into routine clinical practice for cancer 
management, we believe that cost analysis assessments first need to be undertaken. The aim of 
this study was therefore to estimate the net cost impact of non-invasive miRNA testing in place 
of CT scanning for TGCT follow-up (‘aftercare’), performed from the perspective of the US 
healthcare system under various pricing scenarios. This study will facilitate a better 
understanding of the health economic value this tool has in improving management for patients 
with TGCTs, which can be used as a model for other novel biomarkers in different cancer types 
- a perspective not often considered when contemplating a shift of clinical protocol.  
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Methods 
This study was a cost analysis of miRNA testing versus CT scans for follow-up 
assessments in patients previously treated for TGCTs. The model predicted the expected cost 
of aftercare per patient under CT scan based follow-up. The analysis was then repeated, 
substituting miRNA testing for CT scans, and the cost difference between the two was 
examined. We repeated the analysis for different utilization rates of the miRNA test relative to 
CT scanning alone. 
Model structure 
Following initial diagnostic work-up, an orchidectomy is performed with pathological 
confirmation and disease staging using CT. Subsequent treatment depends on staging - stage I 
tumors may be observed in many circumstances, whereas stage II-IV tumors require further 
definitive therapy, usually chemotherapy according to International Germ Cell Consensus 
Classification (IGCCC) risk groups (5,6). The patient then enters aftercare, where the program 
of follow-up depends upon the previous indication, treatment type, stage of disease and the 
number of years in remission.  
A Markov model was developed to estimate the trajectory of patients following initial 
treatment as they entered into long-term monitoring (Supplementary Data). The (US) National 
Comprehensive Cancer Network (NCCN) guidelines for TGCTs recommend a 10-year 
window of monitoring following treatment for all patients (7); consequently the time horizon 
of the model was 10 years. A 1-year transition period for the model was chosen because much 
of the clinical literature supporting transition rates utilised annual data collection windows. 
As the focus of the study was on patient aftercare, parameters relating to initial 
presentation, diagnosis (via orchidectomy) and subsequent staging were omitted, and the model 
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commenced post-orchidectomy, immediately prior to subsequent management (Figure 1). 
Patients entered the model stratified into one of three possible clinical stages I, II, and III; based 
on tumor size, evidence of lymph node involvement, and/or presence of metastases (7) of 
seminoma or nonseminoma [it should be noted that NCCN guidelines for TGCTs exclude stage 
IV as a prognostic grouping (7)]. 
The majority of patients with TGCTs enter remission following treatment, which was 
modelled as a series of ‘follow-up’ tunnel states unique to the patient’s original disease staging 
(Figure 1). Resource usage rates for aftercare at each year of follow-up (Table 1) were based 
on NCCN management guidelines (7) and supplemented by interview with consultant 
oncologists from the UK. Patients within a given year of follow-up could either progress to the 
next year of follow-up, or encounter a relapse. A relapse event was modelled as an 
instantaneous occurrence with a corresponding risk of successful recovery or disease 
progression. Patients with a successful recovery were assumed to have returned to the year one 
follow-up state corresponding to their original diagnosis stage, while patients who progressed 
would receive salvage therapy. It should be noted that death was only modelled following a 
transition into the relapse state, supported by the low mortality rates from active TGCT disease 
and high success rates of treatment (25). 
In the US, according to the Surveillance, Epidemiology, and End Results (SEER) 
database, 58.3% of TGCT patients have seminoma while 41.7% have nonseminoma (26). Year 
0 starting stages were based on the distribution of tumor stages at diagnosis (26). The model 
was populated with data for recurrence risk and relapse mortality from a number of TGCT 
clinical studies (Table 2). A discount rate of 5% was selected based on prior health economic 
precedent to account for the time-value of longitudinal treatments (27). 
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Unit costs for different elements of the aftercare pathway, comprising clinical 
examination, conventional serum AFP/HCG estimation, chest X-rays and CT scans, were 
obtained from a prior analysis examining TGCT treatment costs in the United States Medicaid 
Medicare systems (28) (Table 2). As we knew the unit cost of the proposed miRNA test but 
not the charge price (which includes e.g. workforce and physician costs, hospital overheads) 
we utilised a cost-to-charge ratio of 3.54. This value represents the mark-up typically set by 
healthcare providers for any services delivered to patients, as a scaling factor relative to their 
original procurement price, which in this case was assumed to be equal to manufacturing cost 
(29). Consequently, from an initial unit cost of $55.43, this yielded an estimated charge price 
of $196.21 per test. 
Sensitivity between miRNA and CT scanning (92% and 92.8%, respectively) was 
assumed to be equivalent for the purposes of this analysis. The difference in specificity (91% 
miRNA vs. 98.6% CT), however, was determined to be too substantial to exclude from further 
analysis; a lower specificity leads to a higher false positive rate and the need for unnecessary 
confirmatory CT scans. To account for this, the model assumes independence between repeat 
tests, and adds the cost of an additional confirmatory miRNA test to follow any positive reading 
from the initial screen, reflecting routine clinical practice where AFP/HCG levels are repeated 
when results increase above the reference range in follow-up. 
Approach to analysis 
The model reported annualised probabilities of patient status across different stages of 
seminoma and nonseminoma, namely: follow-up monitoring, recurrence, or death. Based upon 
different patient states, we reported annualized expected treatment and aftercare costs, and 
aggregate distribution of pre-determined expenses within the care process. The results of this 
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analysis and expected service utilization rates were used to project what cost saving impacts 
miRNA testing might have on individuals and the US healthcare system (Supplementary Data; 
Markov model). A one-way sensitivity analysis of all model attributes was conducted to 
understand cost drivers in the aftercare process. 
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Results 
Face validity 
After 1, 5, and 10 years of follow-up, the model predicted overall survival (OS) at 
99.34%, 98.65%, and 98.30% for TGCT patients, respectively (Figure 2). This compares 
favorably with available national-level data. A Cancer Research UK (CRUK) survival analysis 
of TGCT patients indicated 1, 5, and 10-year survival of 99.1%, 98.3%, and 98.2%, 
respectively, suggesting the model has very strong face validity (Table 3) (30). 
Typical cost of care 
The expected costs of providing aftercare services to a patient with TGCT over 10 years 
were calculated to be approximately $19,493 (Figure 3). Of the different services provided, CT 
scans made up the majority of the cost by far, at 56.4% of total expenses, followed by physical 
exams (18%), conventional tumor markers (15.3%), relapse treatment (9.4%) and X-rays 
(0.9%). The majority of expenses were encountered early in the aftercare process, in 
concordance with the increased rate of service utilization during the initial years of post-
treatment follow-up.  
Cost of care - miRNA test 
At a 20% early adoption rate of miRNA testing, the expected cost of providing aftercare 
services to patients with TGCTs over 10 years was estimated to be approximately $17,781, 
which represented a 9% saving in total expenditure compared with CT only (Figure 2). 
Increasing adoption to 100%, the expected cost of aftercare services fell further to $10,933, 
representing a 44% saving. 
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To understand how these savings translated to a systems level, a model of testicular 
cancer incidence was developed using historical data (Appendix A; Supplementary Data) and 
used to estimate the number of new cases annually between 2018 and 2027. Using this model, 
the predicted annual average cost of aftercare services for the US healthcare system was $157M 
over 10 years. Utilization rates of 20% or 100% for miRNA testing would result in 10-year US 
healthcare expenditure savings of $138M and $688M, respectively. Given that the total cost of 
testicular cancer treatment for the US healthcare system has been estimated to be $201M 
annually, including initial treatment (28), the full implementation of miRNA testing has the 
potential to reduce that figure by $69M annually, a 34% reduction in total annual expenditure 
for this disease. 
Sensitivity analysis 
Sensitivity analysis of all variables was conducted under conditions of 20% early test 
adoption. Results showed that the price of a CT scan remained the most influential factor in 
determining the total cost of care (Figure 4). Unsurprisingly, the miRNA utilization rate had a 
larger impact on cost than the price of the miRNA test itself, as higher adoption acted to offset 
the utilization of costly CT scanning in favor of the less expensive blood-based test. Price was 
more sensitive to increases in nonseminoma incidence as compared with seminoma, a 
reflection of the more aggressive nature of nonseminoma, with higher rates of relapse and 
disease-associated mortality.  
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Discussion 
To our knowledge, this report represents the first health economic analysis to assess the 
utility of a non-invasive miRNA test in TGCT clinical practice, with particular regard to 
reducing the use of CT imaging. Reducing the reliance on CT during TGCT follow-up 
monitoring has not only a clinical benefit, but offers significant cost savings to patients, 
providers, and healthcare systems. Previous economic assessments of oncology protocols have 
typically focused on the potential savings obtained through early diagnosis, which requires less 
treatment and is associated with a lower chance of recurrence and higher subsequent quality of 
life (31). TGCTs are atypical in that patients tend to present early and there is a pre-existing, 
low-cost diagnostic protocol in place via ultrasound and orchidectomy. Additionally, TGCT 
treatment is relatively inexpensive in comparison with most other oncology schedules, and is 
very effective; TGCT has one of the highest cancer survival rates (25). Consequently, the 
analysis presented here focuses on the costs arising from aftercare, particularly the substitution 
of imaging studies with lower-cost alternatives.  
The sensitivity and specificity of CT in detecting intra-testicular lesions is 92.8/98.6% 
(23), however, small lesions are often incidental and benign findings (32). Based on prior 
analyses (20,22), the miRNA test developed by our group is likely to have a comparable level 
of sensitivity in detecting TGCT as CT, with sensitivity and specificity of 92% and 91%, 
respectively (22); the lower cost of the test vs. CT offsets the lower specificity.  Indeed, very 
recent data would suggest the superiority of miRNA testing over CT scans for assessing 
patients after chemotherapy for the presence of residual active malignant disease (33). Thus, 
early data suggest that a miRNA test could potentially substitute for a CT scan in aftercare, 
without compromising patient outcomes. The results presented here show that the miRNA test, 
at a basic charge price of $196.21, has the potential to offset a large proportion of aftercare 
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costs as a replacement for CT. Indeed, complete replacement could result in a $688M saving 
to the US healthcare system over a 10 year period. 
Whilst these potential cost savings are compelling for US health insurers, the views of 
physicians and patients should also be considered. Whilst physicians consider cost-savings 
within their practice, this is always a secondary motivator in adoption of new protocols. Indeed, 
multiple behavioral factors influence adoption of such protocols by physicians; one study 
showed that patients received recommended care only 55% of the time (34). Therefore, an 
alternative protocol offering only cost-savings for similar standard-of-care may struggle to gain 
widespread adoption in the short-to-medium term. Importantly, our analysis shows that 
tangible cost-savings would still be accrued even with a modest initial 20% rate of replacement 
over CT scans. For the patient perspective, see Appendix B, Supplementary Data. 
Our model and analyses have a number of potential limitations. Firstly, the variability 
of treatment given and the aftercare process, based on the stage and type of TCGT disease, 
meant that the care pathway required simplification in order to build the model structure. 
Secondly, the healthcare prices used in the model were derived from Medicare/Medicaid claims 
data, which typically underestimates the prices charged for patients with private health 
insurance. This could lead to an underestimate of the cost-savings that could be achieved from 
the miRNA test. In contrast, in other non-US healthcare systems the costs for CT are likely to 
be lower and consequently cost-savings more modest. Thirdly, it is acknowledged that the 
NCCN guidelines for CT scan frequency are not particularly evidence-based, and a more 
measured approach to scanning is adopted in some healthcare systems; such an approach would 
also impact on potential cost-savings. Fourthly, we have assumed that the sensitivity and 
specificity of the miRNA test will be the same at the time of radiologically identified relapse 
as at primary diagnosis. It should be noted that large-scale prospective clinical trials are 
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underway to confirm this assumption. Finally, the initial 20% miRNA test adoption rate was 
selected as the starting value based on interviews with clinical experts, but the real value may 
differ depending upon the degree of clinical evidence, marketing efforts, and other tertiary 
factors that influence the adoption of novel biomarkers. We have however made the model 
available so that it may be adjusted for these and other factors in different healthcare systems 
(Supplementary Data; Markov model). 
In calculating the final cost-offset, miRNA testing frequency and pattern was made 
comparable to the current NCCN guidelines for CT scanning. It is highly likely that when 
implemented in clinical practice, however, the guidelines for miRNA testing will be consistent 
with the more frequent conventional serum tumor marker analyses. Of note, we retained 
conventional AFP/HCG tumor marker utilization in the follow-up care pipeline. Given the 
relatively limited performance of these markers for detecting TGCT relapse, particularly for 
seminoma patients, the potential for replacing both CT scanning and AFP/HCG analysis with 
a single serum miRNA test should also be considered in such cohorts. Further confirmatory 
work will be required to ensure that the sensitivity of the miRNA test is indeed comparable to 
CT scans during aftercare in a clinical setting. Our results provide a strong incentive for such 
work to be conducted. Once undertaken, confirmatory CT will only need to be performed in 
positive miRNA test cases, to allow assessment of radiological extent of disease. Early 
evidence shows that the miRNA test is positive at the time of malignant TGCT relapse and that 
these novel biomarkers may precede clinical or radiological evidence of disease (6,17). 
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Conclusion. Significant costs in TGCT care are incurred by the healthcare system during the 
10-year follow-up or ‘aftercare’ period. We demonstrate the potential cost-offset of adopting 
miRNA testing over CT scans in TGCT aftercare. Our analyses show potential cost-savings at 
a range of adoption levels over CT scans and price points for the test. Following confirmatory 
studies, it will be important to establish miRNA testing in routine TGCT clinical management, 
at which stage the cost effectiveness of this approach can be formally assessed and 
demonstrated.  
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Clinical Practice Points 
 It is already known that the current conventional serum markers alpha fetoprotein 
(AFP) and human chorionic gonadotropin (HCG) have limited sensitivity in assisting 
the diagnosis and longitudinal follow-up of testicular (germ cell) cancer, as they are 
typically negative in certain malignant subtypes, including seminoma and embryonal 
carcinoma. 
 
 It is also known that clinical examination and chest X-ray are of very little use for 
diagnosing relapse in clinical follow-up of testicular cancer patients. 
 
 Consequently, testicular cancer aftercare relies heavily on CT scanning in follow-up, 
with associated radiation burden and concerns regarding second cancer risk, as well as 
health economic implications. 
 
 Recently, serum microRNA testing has shown much research promise as a potential 
universal biomarker of diagnosis and relapse for all malignant germ cell cancers, 
including testicular cancer. 
 
 Prior to the introduction of novel nucleic acid based biomarkers such as circulating 
microRNAs or tumor DNA (ctDNA) into routine clinical practice for cancer 
management, cost analysis assessments need to be undertaken. 
 
 Here, our cost analyses demonstrate a potential cost-offset of adopting miRNA testing 
over CT scans in testicular cancer aftercare. 
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 Following confirmatory prospective studies, it will be important to establish microRNA 
testing in routine testicular cancer clinical management 
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Legends to Figures and Tables 
Figure 1. Markov Chain summarising testicular germ cell tumor (TGCT) aftercare model flow 
structure. At the point marked ‘start’ post-treatment patients are divided into having had either 
seminoma or nonseminoma based upon disease incidence rates of each indication, and 
subsequently divided into stages using similar methods. With the assumption that each patient 
had been treated and is currently in remission, each year of follow-up care is entered. At each 
point, there is a unique risk of relapse that decreases over time. A patient entering relapse either 
successfully recovers, at which point they will return to the beginning of the follow-up cycles, 
or are assumed to have disease progression which leads to death. Patients progress through 
each unique year of follow-up until they reach the Year 10 state, which repeats indefinitely for 
any additional model cycles.  
 
Figure 2. Each possible Markov state following 10 cycles of the testicular germ cell tumor 
(TGCT) aftercare model is shown (A). The horizontal axes represents each individual Markov 
cycle, with point zero showing initial patient stratifications based on disease and stage 
incidence data. The vertical axes represent the total probability of a patient progressing through 
the model being in that particular state (follow-up, relapse, or death) having had either 
seminoma or nonseminoma stages 1, 2 or 3. For each cycle, all model states cumulatively add 
up to 100% probability. The overall survival for patients with seminoma and nonseminoma, 
combined, is shown with data from CRUK superimposed for comparison (B). 
 
Figure 3. The costs of different testicular germ cell tumor (TGCT) aftercare services are shown 
under a 20% miRNA test adoption rate scenario. The absolute expected aftercare costs, 
stratified by service, are shown for each year of follow-up for 10 model cycles (A). The 
cumulative cost of each individual service over 10 model cycles, discounted at a rate of 5% per 
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cycle, is combined to highlight the total expected, discounted, cost of aftercare services (B). 
The impact of varying the miRNA test utilization rate on the total discounted cost of aftercare 
services for individual as well as health system cost is shown (C). 
 
Figure 4. A sensitivity analysis of the testicular germ cell tumor (TGCT) aftercare model was 
conducted under the 20% miRNA test adoption scenario, with each model input varied by -
20% (low) or +20% (high) from its basal condition (Table 2). The impact on total discounted 
cost of aftercare services was then calculated. Results were sorted top-down in order of largest 
absolute difference between low and high cases. 
 
Table 1. Annual frequency of different follow-up service utilization by initial stage and 
condition. The four major follow-up services, namely physical examination, tumor marker 
screening, X-ray and CT scanning, together with miRNA testing, are mapped according to 
stage and either germ cell tumor subtype – either seminoma or nonseminoma. For each year of 
follow-up care after initial treatment, the number of annual recommended service utilizations 
is shown. 
 
Table 2. Markov model inputs. Parameters for input into the model are shown below. The 
upper panel is separated into seminoma and nonseminoma. The lower panel includes treatment 
costs for different follow-up services and relapse treatment. 
 
Table 3. Face validity comparison between model and validation data. Pooled overall 
survival (OS) from both seminoma and nonseminoma branches of the Markov model at various 
time-points are compared against comparable epidemiological data available for CRUK.  
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Table 1. Annual frequency of different follow-up service utilization by initial stage and 
condition. The four major follow-up services, namely physical examination, tumor marker 
screening, X-ray and CT scanning, together with miRNA testing, are mapped according to 
stage and either germ cell tumor subtype – either seminoma or nonseminoma. For each year 
of follow-up care after initial treatment, the number of annual recommended service 
utilizations is shown. 
Condition Stage Service 
Year of Follow-up Care 
1 2 3 4 5 6+ 
Seminoma 
I 
Physical exam 4 4 2 2 1 1 
Tumor markers 4 4 2 1 1 1 
X-ray 0 0 0 0 0 0 
CT Scan 2 2 1 1 1 1 
miRNA test 2 2 1 1 1 1 
II 
Physical exam 4 2 2 2 2 2 
Tumor markers 4 2 2 2 2 2 
X-ray 2 2 1 1 1 1 
CT scan 2 2 1 1 1 1 
miRNA test 2 2 1 1 1 1 
III 
Physical exam 6 4 2 2 2 2 
Tumor markers 6 4 2 2 1 1 
X-ray 6 4 2 2 1 1 
CT scan 4 4 4 4 2 2 
miRNA test 4 4 4 4 2 2 
  
Physical exam 
Tumor markers 
12 
12 
6 
6 
4 
4 
4 
4 
2 
2 
1 
1 
 I X-ray 0 0 0 0 0 0 
  CT scan 4 4 2 2 1 1 
  miRNA test 4 4 2 2 1 1 
 
II 
Physical exam 4 4 2 2 2 1 
 Tumor markers 4 4 2 2 2 1 
Nonseminoma X-ray 6 6 4 2 2 1 
 CT scan 2 2 1 1 1 1 
 miRNA test 2 2 1 1 1 1 
 
III 
Physical exam 6 4 2 2 2 1 
 Tumor markers 6 4 2 2 2 1 
 X-ray 6 6 4 2 2 1 
 CT scan 2 2 1 1 1 1 
 miRNA test 2 2 1 1 1 1 
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Table 2. Markov model inputs. Parameters for input into the model are shown below. The 
upper panel is separated into seminoma and nonseminoma. The lower panel includes treatment 
costs for different follow-up services and relapse treatment. 
Parameter Value Reference* Parameter Value Reference* 
Seminoma  Nonseminoma 
Incidence 58.29% (26) Incidence 41.71% (26) 
Stage At Diagnosis   Stage At Diagnosis   
Stage I  80.21% (26) Stage I  58.20% (26) 
Stage II  15.04% (26) Stage II  23.34% (26) 
Stage III  4.75% (26) Stage III  18.46% (26) 
Recurrence Risk   Recurrence Risk   
Stage I   Stage I   
Year I 5.4% (9) Year I 15.0% (9) 
Year II 4.2% (9) Year II 2.3% (9) 
Year III 2.2% (9) Year III 0.7% (9) 
Year IV 1.35% (35) Year IV 0.68% (35) 
Year V 0.46% (35) Year V 0.65% (35) 
Year VI 0.37% (35) Year VI 0.53% (35) 
Year VII 0.28% (35) Year VII 0.41% (35) 
Year VIII 0.19% (35) Year VIII 0.28% (35) 
Year IX 0.09% (35) Year IX 0.16% (35) 
Year X 0.0% (35) Year X 0.04% (35) 
Stage II   Stage II   
Year I 3.1% (25) Year I 3.1% (25) 
Year II 1.0% (25) Year II 1.0% (25) 
Year III 1.0% (25) Year III 1.0% (25) 
Year IV 1.0% (35) Year IV 0.71% (35) 
Year V 1.0% (35) Year V 0.40% (35) 
Year VI 0.82% (35) Year VI 0.36% (35) 
Year VII 0.63% (35) Year VII 0.31% (35) 
Year VIII 0.45% (35) Year VIII 0.26% (35) 
Year IX 0.26% (35) Year IX 0.22% (35) 
Year X 0.08% (35) Year X 0.17% (35) 
Stage III   Stage III   
Year I 3.1% (25) Year I 3.1% (25) 
Year II 1.0% (25) Year II 1.0% (25) 
Year III 1.0% (25) Year III 1.0% (25) 
Year IV 0.51% (35) Year IV 0.93% (35) 
Year V 0.0% (35) Year V 0.85% (35) 
Year VI 0.0% (35) Year VI 0.74% (35) 
Year VII 0.0% (35) Year VII 0.62% (35) 
Year VIII 0.0% (35) Year VIII 0.50% (35) 
Year IX 0.0% (35) Year IX 0.38% (35) 
Year X 0.0% (35) Year X 0.26% (35) 
Relapse Survival   Relapse Survival   
Stage I  99.1% (36) Stage I  99.0% (36) 
Stage II/III  32.7% (5) Stage II/III  39.7% (5) 
Treatment Costs 
Cost Physical Exam $164.29 (28) Cost Radiotherapy (RT) 
Course 
$12,927.48 (28) 
Cost Tumor Markers $142.68 (28) Cost Surgery $11,595.09 (28) 
Cost Chest X Ray $29.95 (28) Cost Total Seminoma 
Relapse 
$11,918.29 (28) 
Cost CT Scan $898.30 (28) Cost Total Nonseminoma 
Relapse 
$11,314.16 (28) 
Cost miRNA $196.21 See Appendix Cost Salvage Chemotherapy $21,804.75 (28) 
Cost Bleomycin, Etoposide, 
Cisplatin (BEP)  Course 
$8,239.87 (28)    
*Detailed data derivations from sources used are available in Supplementary Data 
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Table 3. Face validity comparison between model and validation data. Pooled overall 
survival (OS) from both seminoma and nonseminoma branches of the Markov model at 
various time-points are compared against comparable epidemiological data available for 
CRUK. 
Time Point Model Overall 
Survival 
CRUK Validation Cohort 
Overall Survival 
% Error 
1 Year 99.34% 99.1% 0.24% 
5 Year 98.65% 98.3% 0.35% 
10 Year 98.30% 98.2% 0.10% 
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 33 
Figure 4 
 
